The effect of initial treatment of periodontitis on systemic markers of inflammation and cardiovascular risk: a randomized controlled trial.
Observational studies indicate that chronic periodontal disease is associated with adverse cardiovascular outcomes. The aim of this study was to determine whether initial periodontal treatment has a beneficial effect on systemic markers of inflammation and cardiovascular risk. One hundred and thirty-six adults with chronic periodontitis were allocated to either intervention or control groups in a 3-month randomized controlled intervention study. The intervention group received initial periodontal treatment, whereas the control group did not receive that treatment until after the study. Blood levels of cardiovascular risk factors, and of hematological, inflammatory, and metabolic markers, were measured at the beginning and the end of the study, and differences were calculated. Fibrinogen level was the primary outcome measure. Data for 61 persons in the intervention group and for 64 persons in the control group were available for statistical analysis. Compared with the control group, the intervention group showed a non-significant trend for a lower fibrinogen level. Significant increases in hemoglobin and hematocrit were seen after treatment, showing that initial periodontal treatment, a relatively simple and cost-effective intervention, has systemic effects.
Taylor
Barbara
B
Sydney Dental Hospital, Surry Hills, Sydney, NSW, Australia.
Tofler
Geoffrey
G
Morel-Kopp
Marie-Christine
MC
Carey
Helen
H
Carter
Torren
T
Elliott
Margaret
M
Dailey
Colette
C
Villata
Luke
L
Ward
Christopher
C
Woodward
Mark
M
Schenck
Karl
K
D000328:Adult; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000097:blood* / Q000209:etiology; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D055113:Chronic Periodontitis / Q000097:blood / Q000628:therapy*; D005260:Female; D005340:Fibrinogen / Q000032:analysis*; D005500:Follow-Up Studies; D005884:Gingival Hemorrhage / Q000628:therapy; D005889:Gingival Recession / Q000628:therapy; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D018655:Lymphocyte Count; D008297:Male; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000628:therapy; D010514:Periodontal Pocket / Q000628:therapy; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D011446:Prospective Studies; D012307:Risk Factors; D010959:Tissue Plasminogen Activator / Q000097:blood; D016896:Treatment Outcome; D014841:von Willebrand Factor / Q000032:analysis
D015415:Biomarkers; D008076:Cholesterol, HDL; D006454:Hemoglobins; D018836:Inflammation Mediators; D017395:Plasminogen Activator Inhibitor 1; D014841:von Willebrand Factor; D005340:Fibrinogen; D002097:C-Reactive Protein; D002784:Cholesterol; D010959:Tissue Plasminogen Activator